| Quarter | Score |
|---|---|
| 2022-Q1 | 49.3 |
| 2022-Q3 | 65.5 |
| 2022-Q4 | 49.3 |
| 2023-Q1 | 49.1 |
| 2023-Q2 | 63.4 |
| 2023-Q3 | 48.0 |
| 2023-Q4 | 65.6 |
| 2024-Q1 | 62.4 |
| 2024-Q2 | 51.6 |
| 2024-Q3 | 75.6 |
| 2024-Q4 | 73.4 |
| 2025-Q1 | 73.5 |
| 2025-Q2 | 77.9 |
| 2025-Q3 | 75.3 |
| 2025-Q4 | 74.5 |
| 2026-Q1 | 75.2 |
| 2026-Q2 | 60.9 |
Funds reducing exposure or consensus momentum fading
Trading +13.3% above funds' estimated purchase price
2 of 18 tracked funds hold LILAK. Avg conviction: 0.4%. Net holding. First tracked at $7.85 (current +13.3% vs tracked).
Oaktree Capital has 0.8% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Oaktree Capital | 0.8% | Add |
| Citadel Advisors | 0.0% | Reduce |